You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.
Researchers' picks range from emerging tools like deep learning to fundamental issues like false discovery rates and infrastructure for mass spec data sharing.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
The company published a letter on its website explaining that the genetic and other analyses involved in its services were too costly for customers to support.
Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.
Researchers reported on results for more than 100 healthy individuals who were tracked with 'omics and clinical tests over nine months.
The company, still collecting utility data, anticipates that this more complex analysis will lead to better personalization of health and wellness strategies for its clients.
ISB President and Co-founder Lee Hood will join Providence as senior VP and chief science officer as the partners join forces on research.
The approach could allow for unbiased detection of protein modifications with greater sensitivity than is possible using conventional shotgun mass spec.
President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.
A study of Great Danes homes in on a genomic region linked to fearfulness.
CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.
In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.